Site web: http://www.revance.com

Numéro de stand :

Catégorie

• Injectables: Toxines botuliniques
• Injectables: Produits de comblement
• Pratiques de gestion: Services commerciaux - Logiciels

Profil de l'entreprise

Revance® is creating a new neuromodulator category, and true innovation in aesthetic medicine and therapeutic specialties with their lead investigational product candidate, DaxibotulinumtoxinA for Injection (DAXI). In the Phase 3 SAKURA clinical trials, DAXI achieved unrivalled efficacy, including a median 24-week duration of effect in treating glabellar lines. Revance’s open-label, long-term safety study, SAKURA 3, was the largest clinical program of an aesthetic neuromodulator, and included nearly 2,700 patients and more than 3,800 treatments. Revance anticipates commercial launch in 2020 upon FDA approval.